Business Model Breakdown
How Abeona Therapeutics Inc Makes Money
ABEO
Market Cap
$292M
Annual Revenue
$6M
Profit Margin
0.0%
Employees
136
The Short Version
Abeona Therapeutics is a clinical-stage and commercial-stage biopharmaceutical company focused on developing and delivering gene and cell therapies for rare diseases. Its primary business currently revolves around the commercialization of ZEVASKYN, an FDA-approved gene therapy used to treat dystrophic epidermolysis bullosa (RDEB), an ultra-rare genetic skin disorder. The company generates revenue by selling this specialized therapy to patients who receive treatment at qualified medical centers, aiming to address critical unmet medical needs with innovative genetic solutions.
Where the Revenue Comes From
ZEVASKYN product sales (~100% of product revenue, Q4 2025: $2.4M product revenue, Total revenue $5.4M implies other sources like R&D grants or licensing)
Who buys: Patients diagnosed with RDEB, treated at specialized Qualified Treatment Centers.
Why It Works (Competitive Advantages)
- ✔First-in-class FDA-approved gene therapy for RDEB
- ✔Regulatory exclusivity (Orphan Drug Designation, Breakthrough Therapy)
- ✔Strong intellectual property protection for ZEVASKYN
Economic Moat: Narrow (Intangible Assets/IP, Regulatory Moat)
What Our Analysis Says
DVR Score as of April 12, 2026
Abeona Therapeutics maintains high 10x potential, primarily driven by its first-in-class FDA-approved gene therapy, ZEVASKYN, for the ultra-rare RDEB, establishing a significant regulatory moat in a market with critical unmet needs. The substantial cash position of $191.4M provides a crucial runway for commercialization. While Q4 2025 results confirmed a slow commercial ramp ($5.4M revenue miss, $2.4M product revenue), recent news of NewYork-Presbyterian/Columbia activating as a Qualified Treatment Center for ZEVASKYN signals progress in addressing execution challenges. The addition of an independent director and a disclosed 5.3% institutional stake offer governance improvement and validation. However, underlying operations remain deeply unprofitable (Q4 loss $20.5M), analyst EPS estimates for FY2026 are negative, and dilution has been substantial. Insider selling (unnamed) slightly tempers enthusiasm, yet the long-term vision and recent commercialization steps keep the high-risk, high-reward thesis intact.